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Service, Johannesburg, South AfricaAbstractGroup B Streptococcus (GBS) rectovaginal colonization in pregnant women is associated with invasive GBS disease in newborns, preterm
delivery and stillbirths. We studied the association of GBS serotype-speciﬁc capsular polysaccharide (CPS) antibody on new acquisition
and clearance of rectovaginal GBS colonization in pregnant women from 20 weeks until 37 to 40 weeks’ gestation. Serum serotype-
speciﬁc CPS IgG antibody concentration was measured by multiplex enzyme-linked immunosorbent assay and opsonophagocytic activity
(OPA) titres. Rectovaginal swabs were evaluated for GBS colonization, using standard culture methods and serotyping by latex
agglutination, at ﬁve to six weekly intervals. Higher serotype III CPS antibody concentration was associated with lower risk of rectovaginal
acquisition of serotype III during pregnancy (p 0.009). Furthermore, serotype-speciﬁc OPA titres to Ia and III were higher in women who
remained free of GBS colonization throughout the study compared to those who acquired the homotypic serotype (p <0.001 for both
serotypes). Serum CPS IgG values of 1 μg/mL for serotype V and 3 μg/mL for serotypes Ia and III were signiﬁcantly associated with
protection against rectovaginal acquisition of the homotypic serotype. A GBS vaccine that induces sufﬁcient capsular antibody in pregnant
women, including high OPA titres, could protect against rectovaginal colonization during the latter half of pregnancy.
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E-mail: shabirm@nicd.ac.zaIntroductionMaternal rectovaginal colonization with group B Streptococcus
(GBS) is the major risk factor for GBS invasive disease in
newborns under 7 days of age (early-onset disease; EOD) [1,2].
Vertical transmission of GBS occurs to approximately 50% of
newborns of GBS-colonized pregnant women, of whom 1% toMicrobiol Infect 2015; 21: 568.e13–568.e21
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.01.0302% develop EOD in the absence of intrapartum antibiotic
prophylaxis (IAP) [3,4]. Rectovaginal GBS colonization of
pregnant women has also been associated with preterm birth
and stillbirth [5]. Screening for GBS rectovaginal colonization in
pregnant women at 35 to 37 weeks’ gestation, coupled with IAP
during labor, has reduced the incidence of EOD in high-income
settings [6]. However, implementation of IAP would be costly
and logistically challenging for most resource-constrained
countries [7,8].
An alternate preventive strategy against invasive GBS disease
in newborns and young infants could be vaccination of pregnant
women with a GBS vaccine to induce humoral immunity, with
protective antibodies transplacentally transferred to the fetus
[9]. An association between low maternal serotype-speciﬁcious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Kwatra et al. Immunity against Streptococcus rectovaginal colonization 568.e14capsular antibody concentration and increased risk of invasive
GBS disease among newborns has been observed [10–12].
Furthermore, if GBS vaccination before or during the early
stages of pregnancy could prevent or reduce subsequent rec-
tovaginal colonization in women, this could lower fetal/
newborn exposure to GBS and contribute to reducing EOD
among term and preterm births as well as potentially reduce
GBS-associated premature labor and stillbirth.
Although spontaneous clearance and acquisition of GBS has
been reported in pregnant women, the association of host
immune mediators and GBS colonization during pregnancy
remains unclear [13,14]. A few predominantly cross-sectional
studies have reported higher serotype-speciﬁc capsular poly-
saccharide (CPS) antibody in colonized compared to non-
colonized women [15–22]. We are, however, unaware of any
longitudinal cohort study which evaluated the association be-
tween serotype-speciﬁc CPS antibody and subsequent risk of
GBS rectovaginal acquisition during the latter half of pregnancy.
The primary objective of our study was to evaluate the as-
sociation between natural serotype-speciﬁc serum CPS IgG
antibody and opsonophagocytic activity (OPA) in relation to
GBS rectovaginal acquisition in pregnant women from 20 to
37 + weeks’ gestation. Furthermore, we evaluated the associ-
ation between CPS antibody and clearance of GBS colonization.MethodsStudy population
The study was conducted at four antenatal community clinics in
Soweto, Johannesburg, from August 2010 to August 2011. In-
clusion criteria were HIV-uninfected pregnant women
(conﬁrmed by HIV enzyme-linked immunosorbent assay non-
reactivity) at 20 to 25 weeks’ gestation. Exclusion criteria
included antibiotic treatment in the previous 2 weeks, any acute
illness, symptomatic vaginal discharge and a known or sus-
pected condition contraindicating a vaginal examination. If an-
tibiotics were taken after the ﬁrst visit, the collection of study
specimens was delayed for at least 2 weeks after the last dose.
Swab collection for GBS culture and serotyping
Lower vaginal and rectal swabs were collected for GBS culture
at 20 to 25 weeks’ gestation (visit 1), followed at ﬁve to six
weekly intervals (visits 2 and 3), and ﬁnally at 37 to 40 weeks’
gestation (visit 4). Samples were collected by trained study
nurses with rayon-tipped swabs that were placed into Amies
transport medium without charcoal (Transwab Amies; Medical
Wire, UK). For GBS isolation, swabs were inoculated onto
CHROMagar StrepB (CA; Media Mage, South Africa) as previ-
ously described [23]. Serotyping was performed by the latexClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeagglutination method with speciﬁc antisera (Statens Serum
Institute, Sweden) to serotypes Ia, Ib and II to IX CPS antigens,
as previously described [24]. Isolates testing negative by latex
agglutination were further typed by PCR using primer se-
quences described by Poyart et al. [25].
Measurement of serotype-speciﬁc anticapsular serum
IgG
Blood was collected at enrolment and visit 4. Serum was
separated by centrifugation and stored at −70 °C until analysis.
Quantitative serum serotype-speciﬁc CPS IgG antibody con-
centrations were measured with the multiplex Luminex plat-
form. All GBS CPS antigens were kindly provided by Novartis
Vaccines, Italy, and were coupled to the microsphere beads
(Bio-Rad, USA) with the cross-linking agent 4-(4,6-dimethoxy
[1,3,5]triazin-2-yl)-4-methyl-morpholinium (DMTMM) as pre-
viously described [26]. An in-house reference serum
composed of puriﬁed pooled human IgG (Polygam; National
Bioproducts, South Africa) was calibrated with the standard
serotype-speciﬁc GBS reference serum kindly provided by C.
J. Baker (Section of Infectious Diseases, Department of Pedi-
atrics, Baylor College of Medicine, AHouston, TX, USA). As-
says were performed in true duplicate and each plate included
high and low control sera. Bead ﬂuorescence was read with
the Bio-Plex 200 instrument (Bio-Rad) using Bio-Plex manager
5.0 software (Bio-Rad). In each assay, an uncoated control
bead was included to determine nonspeciﬁc binding. For
control beads, the coupling procedure was followed, except
that no GBS CPS was added. In case of nonspeciﬁc binding, the
ﬂuorescence intensity values were subtracted from the
antigen-speciﬁc results. The optimal serum and secondary
antibody dilution was 1:100. The results for serum CPS IgG
are given in μg per mL with lower detection limits of 0.0003,
0.005 and 0.009 for serotype Ia, III and V, respectively. For
statistical analysis, samples with values below these limits were
assigned values of half of lower limit of detection.
The multiplex assay was validated by comparing the
serotype-speciﬁc mean ﬂuorescence intensity values for Poly-
gam obtained with the multiplex assay with those for each
serotype run in single plex. The ﬂuorescence intensity values
obtained for Polygam with the multiplex assay were between
79% and 112% (median 103%) of those obtained with the single-
plex assays. To assess analytical speciﬁcity of each GBS–
microsphere set, Polygam was incubated at 1:100 dilution with
each GBS CPS (100 μg/mL) and incubated at 37°C for 2 hours.
The speciﬁcity was recorded as the difference in reactivity
between the absorbed and unabsorbed sera in a multiplex
assay. Homologous inhibition was >95% for all serotypes, with
the exception of serotype V (85%). Heterologous inhibition
across serotypes was <10%, except for serotypes Ib and III,ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e13–568.e21
568.e15 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIwhich were inhibited by 41% and 11% with type Ia CPS,
respectively, and serotype V (18%) was inhibited by serotype III
CPS.
Serum IgG OPA assay
The functional activity of serum IgG was determined by OPA
assay for serotypes Ia and III using the HL-60 cell line as
described [27]. Brieﬂy, 1000 CFU (20 μL of 5 × 104 CFU/mL)
of GBS type Ia strain (A909) or type III strain (COH-1) cells
were mixed with an appropriate dilution of heat-inactivated
serum sample (10 μL), then mixed and incubated for 15 mi-
nutes at 37°C in a 5% CO2 incubator. Baby rabbit complement
(10 μL) and HL-60 cells (40 μL of 1 × 107, cultured for 5 days
in the presence of dimethyl formamide) were added to the
mixture and incubated at 37°C with 5% CO2 for 1 hour with
gentle agitation. Aliquots were removed and plated on Todd-
Hewitt agar plates for quantitative culture. OPA was
expressed as the titre at which the serum dilution yielded 50%
killing compared to the bacterial growth in the complement
controls. The limit of detection was 8. For statistical analysis,
samples below the detection were assigned an arbitrary titre
of 4.
Study deﬁnitions
A participant was considered to be colonized at a visit if GBS
was cultured on the vaginal and/or rectal swab, and non-
colonized if no growth was detected from either swab. A new
episode of serotype-speciﬁc GBS rectovaginal colonization (i.e.
new acquisition group) was deﬁned as a participant not colo-
nized by a speciﬁc GBS serotype at visit 1 who was subse-
quently colonized by that speciﬁc serotype (irrespective of the
number of study visits completed). Concurrent identiﬁcation of
different serotypes from the vaginal and rectal swabs at a visit
among participants with new acquisitions were treated as in-
dividual events. Participants not colonized with a speciﬁc
serotype at any study visit were categorized as being the non-
colonized group for that serotype and were used as the
comparator group when evaluating the association between
CPS antibody and risk for serotype-speciﬁc rectovaginal
acquisition.
The association of CPS antibody with clearance of serotype-
speciﬁc GBS colonization was evaluated in participants who
were colonized by the speciﬁc serotype at visit 1 and who
completed all study visits. The participants were stratiﬁed into
those who remained colonized throughout (i.e. persistently
colonized group) and those in whom colonization of speciﬁc
serotype was cleared by visit 4 (i.e. intermittently colonized
group). As a result of limitations associated with detecting
multiple serotype carriage using traditional culture methods
[28], participants with GBS serotype colonization at visit 1 whoClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectacquired a different GBS serotype at a subsequent visit were
excluded from the analysis on CPS antibody and serotype-
speciﬁc GBS acquisition or clearance.
Statistical analysis
Differences in geometric mean concentration (GMC) of
serotype-speciﬁc CPS antibody and geometric mean OPA titre
(GMOPT) between groups (new acquisition vs. noncolonized
groups; and persistently colonized vs. intermittent colonized
groups) were analysed on log-transformed data by Student’s t
test. GMC values at visits 1 and 4 for each group were analysed
by paired Student’s t test. Evaluation of whether the serotype-
speciﬁc CPS antibody was associated with new homotypic GBS
acquisition was undertaken using univariate logistic regression
analysis reporting the odds ratio (OR) for the association be-
tween the serological variable and GBS acquisition, with loga-
rithmic IgG or OPA titre as a covariate. Univariate logistic
regression analysis was also used for comparison between
groups by demographic and obstetric factors at visit 1.
For categorical variables, groups were compared by either
the chi-square test or Fisher’s two-tailed exact test, as appro-
priate. Correlations between serum IgG and OPA titres were
determined on log-transformed data by Spearman rank corre-
lation. Data were analysed using SAS software, version 9.2 (SAS
Institute, USA). A p value of <0.05 was considered signiﬁcant.
Ethics Statement
The study was approved by the Human Research Ethics
Committee of the University of the Witwatersrand (IRB/Pro-
tocol-M090937), and informed written consent was obtained
from all participants. This observational study was registered
with the South African National Clinical Trials Register (DOH-
27-0210-3012).ResultsOf 661 enrolled participants, 95.1% (n = 629) completed at
least two and 76.7% (n = 507) all four study visits. The main
reasons for not completing all study visits were related to ob-
stetric outcomes such as premature birth (n = 86; 13.0%) and
miscarriage (n = 13; 2.0%; Supplementary Fig. 1). A detailed
proﬁle of subject follow-up, serotype distribution and dynamics
of GBS colonization has been previously published [29].
The overall prevalence of any serotype GBS colonization at
enrolment was 33.0% (218/661).
Of those not colonized by GBS serotypes Ia, III or V at
enrolment, 9.6% (52/541), 7.0% (39/560) and 2.8% (17/603)
subsequently become colonized by the respective serotypes
(i.e. new acquisition group). This included six participants forious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e13–568.e21
CMI Kwatra et al. Immunity against Streptococcus rectovaginal colonization 568.e16whom different serotypes were cultured from the vaginal and
rectal site at the same visit and excluded 15 participants who
were colonized at visit 1 and acquired a different serotype at a
subsequent visit. Of 507 participants who completed all
scheduled visits, participants not colonized with a speciﬁc
serotype at any visit were 387 (76.3%), 414 (81.6%) and 471
(92.9%) for serotypes Ia, III and V, respectively (i.e. non-
colonized group). There were no differences in the de-
mographic characteristics between the new acquisition and
noncolonized groups (Table 1).
Of the 507 participants who completed all scheduled visits,
the overall GBS colonization prevalence at enrolment was
32.1% (163/507), including 14.0% (n = 71), 11.1% (n = 56) and
2.9% (n = 15) for serotypes Ia, III and V, respectively. The
prevalence of serotypes Ia, III and V colonization among the
persistently colonized group were 4.1% (21/507), 5.3% (27/507)
and 0.4% (2/507), respectively; and 8.5% (43/507), 3.6% (18/
507) and 1.8% (9/507), respectively, in the intermittent colo-
nized group. This excluded 22 intermittently colonized partic-
ipants in whom colonization was not cleared by visit 4 or who
acquired a new serotype at subsequent visits and who remained
colonized with that serotype thereafter. There were no dif-
ferences in the demographic characteristics between the
persistently colonized and intermittent colonized groups (data
not shown).
Association between serotype-speciﬁc CPS IgG and
new acquisition of the homotypic serotype
The logistic regression analysis for the association between
homotypic serotype acquisition and serotype-speciﬁc IgG
concentration at enrolment demonstrated an OR of <1.00,
indicating that the probability of a new acquisition decreased
with increasing serotype-speciﬁc IgG concentrations (Table 2).
Homotypic serotype antibody GMC was higher at enrolment
among the noncolonized than the new acquisition group for
serotype III (0.33 μg/mL vs. 0.17 μg/mL, respectively; p 0.009),TABLE 1. Demographic characteristics of women who acquired
compared to those who remained noncolonized by that serotype t
Characteristic
Serotype Ia Serotype II
New acquisition Not colonized
p
New acquis
(n [ 52) (n [ 387) (n [ 39)
Age (years), mean ± SD 25.65 ± 5.76 26.06 ± 5.54 0.619 26.13 ± 6.2
Parity, median (range) 1 (0–5) 0 (0–5) 0.582 0 (0–3)
Gravidity, median (range) 2 (1–6) 2 (1–8) 0.891 1 (1–4)
Previous spontaneous
abortion, n (%)
6 (11.5) 64 (16.5) 0.358 4 (10.2)
Previous stillbirth, n (%) 2 (3.8) 4 (1.0) 0.127 0 (0.0)
New acquisition was deﬁned as women who acquired serotype-speciﬁc new acquisition; nonc
four study visits; spontaneous abortion was deﬁned as the spontaneous abortion of pregnancy
at 28 weeks’ gestation or later. p values were calculated by univariate logistic regression an
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infewith a similar trend for serotype V (0.75 μg/mL vs. 0.42 μg/mL,
respectively; p 0.057) (Table 2).
Reverse cumulative distribution plots of serotype-speciﬁc
CPS antibody concentrations of the noncolonized and new
acquisition groups are shown in Fig. 1a–c. The lowest threshold
of CPS antibody concentration associated with lower odds of
acquisition of the homotypic serotype varied between sero-
types. The lowest antibody threshold signiﬁcantly associated
with remaining noncolonized throughout the study was 3 μg/
mL for serotype Ia (22.0% in noncolonized vs. 9.6% in new
acquisition group, OR 0.37; 95% conﬁdence interval (CI)
0.14,0.98), 3 μg/mL for serotype III (10.6% in noncolonized
vs. 0.0% in new acquisition group, OR 0.11; 95% CI 0.01–1.75)
and 1 μg/mL for serotype V (36.5% in noncolonized vs. 11.8%
in new acquisition group, OR 0.23; 95% CI 0.05–1.02; Table 3).
This strength of association increased at higher CPS antibody
thresholds for serotypes Ia and III (Table 3). None of the
women who acquired serotype Ia had antibody concentration
of 15 μg/mL (compared to 8.5% of noncolonized women, p
0.025) at enrolment; and none with new acquisition of sero-
types III had homotypic CPS antibody 3 μg/mL (compared to
10.6% (p 0.023) of those who remained noncolonized; Table 3).
Association between serotype-speciﬁc OPA and new
acquisition of GBS
Reverse cumulative distribution plots of serotype-speciﬁc OPA
titres of the noncolonized and new acquisition groups for se-
rotypes Ia and III are shown in Fig. 1d, e. The logistic regression
analysis for the probability of acquisition of GBS serotypes Ia
and III as a function of homotypic serotype OPA titre at
enrolment had an OR of <1.00, indicating that the probability of
a new acquisition decreased with increasing serotype-speciﬁc
OPA titre (Table 2). Noncolonized women had higher
serotype-speciﬁc GMOPT than the new acquisition group for
serotypes Ia (GMOPT: 14 vs. 5, respectively; p < 0.001) and III
(GMOPT: 132 vs. 20, respectively, p < 0.001; Table 2). Thea speciﬁc group B Streptococcus serotype (new acquisition)
hroughout the study
I Serotype V
ition Not colonized
p
New acquisition Not colonized
p(n [ 414) (n [ 17) (n [ 471)
26.10 ± 5.6 0.969 26.01 ± 4.77 26.06 ± 5.66 0.955
0 (0–5) 0.556 1 (0–1) 0 (0–5) 0.751
2 (1–8) 0.353 2 (1–3) 2 (1–8) 0.500
70 (16.9) 0.289 1 (5.9) 80 (17.0) 0.253
6 (1.4) 0.449 0 (0.0) 7 (1.5) 0.612
olonized was deﬁned as women who remained uncolonized by speciﬁc serotype at all
occurring before 28 weeks’ gestation; and stillbirth was deﬁned as fetal death occurring
alysis.
ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e13–568.e21
TABLE 2. Comparison of mean titres (μg/mL) at visit 1 for pregnant women for speciﬁc serotypes
Serotype
New acquisition Noncolonized
pa Odds ratio (95% CI)bGMC (95% CI) GMC (95% CI)
Ia 0.28 (0.17, 0.47); n = 52 0.35 (0.27, 0.44); n = 387 0.529 0.91 (0.68, 1.21)
III 0.17 (0.11, 0.26); n = 39 0.33 (0.28, 0.38); n = 414 0.009 0.47 (0.26, 0.84)
V 0.42 (0.26, 0.65); n = 17 0.75 (0.66, 0.84); n = 471 0.057 0.39 (0.15, 1.01)
OPA GMOPT (95% CI) GMOPT (95% CI)
Ia 5 (4, 6); n = 52 14 (11, 17); n = 387 <0.001 0.28 (0.12, 0.63)
III 20 (11, 36); n = 39 132 (105, 164); n = 414 <0.001 0.43 (0.30, 0.62)
New acquisition indicates women who acquired serotype-speciﬁc new acquisition; noncolonized indicates women who remained uncolonized by speciﬁc serotype.
CI, conﬁdence interval; GMC, geometric mean concentration; GMOPT, geometric mean opsonophagocytic activity titre; OPA, opsonophagocytic activity.
ap value calculated by Student’s t test.
bOdds ratio calculated by logistic regression analysis.
568.e17 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIpresence of detectable OPA titres (8) was signiﬁcantly asso-
ciated with lower odds of acquiring the homotypic serotype for
Ia (p 0.002) and III (<0.001). The strength of association be-
tween OPA titres and odds of new acquisitions trended to be
stronger at higher OPA threshold for serotypes Ia and III
(Table 3).
There were signiﬁcant correlations between serum IgG
concentration and OPA titre with r values of 0.684 for serotype
Ia and 0.393 for serotype III (p <0.001 for both) (Supplementary
Fig. 2a, b). OPA activity (titre 8) was detectable to the
homotypic serotype in 92% (138/150) of serum samples with
IgG concentration 3 μg/mL for serotype Ia and 94.1% (192/
204) of samples with IgG concentration 0.5 μg/mL for sero-
type III.
Association between serotype-speciﬁc CPS IgG and
clearance of colonization at enrolment
Serotype-speciﬁc CPS antibody concentration was greater
among women colonized compared to those not colonized by
the homotypic serotype at visit 1 for serotype Ia (p 0.025) and
serotype III (p 0.018); and at visit 4 for serotype Ia (p < 0.001)
with similar trend for serotype III (p 0.060), although this was
not statistically signiﬁcant for OPA at visit 1 (Supplementary
Table 1). Among women colonized at enrolment, higher CPS
GMC (1.49 vs. 0.44 μg/mL, p 0.049) and GMOPT (41 vs. 12; p
0.025) were observed for serotype Ia in those categorized as
persistently colonized than those with intermittent coloniza-
tion, respectively, but not so for serotypes III and V
(Supplementary Table 2).
Effect of GBS colonization on kinetics of serotype-
speciﬁc antibody
When we analysed women who completed all four study visits
and who were not colonized by a speciﬁc serotype at enrol-
ment, serotype-speciﬁc new acquisition was associated with an
increase in GMC and GMOPT values between enrolment and
visit 4. These increases were evident for GMC for serotype IaClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect(p 0.001), III (p 0.004) and V (p 0.034), as well as GMOPT for
serotypes Ia and III (p < 0.001 for both; Table 4). For serotype
Ia, a new acquisition event was also associated with an increase
in correlation between serotype-speciﬁc serum IgG concen-
tration and OPA titres, with r values of 0.524 at enrollment
(p < 0.001) and 0.792 at visit 4 (p < 0.001) (Supplementary
Fig. 2c, d). In contrast, for serotype III, a decrease in correla-
tion between enrollment (r = 0.354, p 0.037) and visit 4
(r = 0.266, p 0.122) was observed, despite signiﬁcant increases
in OPA titres (Supplementary Fig. 2e, f). No change was
observed in GMC between visits 1 and 4 among women who
remained noncolonized by the speciﬁc serotype throughout the
study for serotypes Ia or III, although an increase was observed
for serotype V (0.83 vs. 0.75 μg/mL, p 0.011).DiscussionOur study demonstrated an association between naturally ac-
quired serum serotype-speciﬁc CPS antibody and the risk of
subsequent rectovaginal colonization by the homotypic sero-
type in pregnant women not colonized at enrolment. New
acquisition of GBS was inversely correlated with serotype-
speciﬁc CPS IgG concentration (serotypes III and V) and OPA
titre (serotypes Ia and III) at time of enrolment. These data
suggest that strategies such as vaccination of women with GBS
CPS–protein conjugate vaccine which induces antibody re-
sponses (Hyderman RF, et al. Program and Abstracts of the
32nd European Society for Paediatric Infectious Diseases) could
reduce the risk of GBS rectovaginal acquisition of vaccine se-
rotypes. The potential beneﬁt to the women and their new-
borns would, however, be dependent on the timing of
vaccination in the women and durability of persistence of suf-
ﬁciently high antibody concentrations or OPA titres to prevent
GBS acquisition during pregnancy. The potential of protein–
polysaccharide conjugate vaccine to induce mucosal immunity
has been demonstrated for vaccines against Haemophilusious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e13–568.e21
(a) (b)
(c)
(d) (e)
FIG. 1. Reverse cumulative distribution curves of serotype-speciﬁc anticapsular serum IgG (a–c) and OPA titre (d–e) in participants who acquired
GBS serotype (new acquisition) and those who remained uncolonized by the speciﬁc serotype (noncolonized).
CMI Kwatra et al. Immunity against Streptococcus rectovaginal colonization 568.e18inﬂuenzae type b, Streptococcus pneumoniae and Neisseria men-
ingitidis in which reduced risks of nasopharyngeal mucosal
colonization acquisition of the targeted serotypes are evident
[30–32].
In our study, the CPS antibody, including functional antibody
measured by OPA, was most likely induced by rectovaginal
colonization, as indicated by the rise in serotype-speciﬁc GMC
and GMOPT among those with new acquisitions of homotypic
serotypes. It is this increase in CPS antibody which likelyClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infereduces the risk of these women becoming colonized by the
same serotype. Although our study was not designed to
establish the durability of this natural-acquired humoral-medi-
ated immunity, the strengthening of association between higher
serotype-speciﬁc antibody thresholds and OPA titres and the
reduced odds of becoming colonized by the homotypic sero-
type indicates that this protection is likely to be transient, with
waning of antibody over time. Also, the paradoxically higher
GMC and GMOPT in women colonized with serotype Ia atctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e13–568.e21
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Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectenrolment who remained persistently colonized thereafter,
compared to those who were only intermittently colonized,
indicates that the antibody which was likely induced by colo-
nization might not clear existing colonization. This clearance of
established colonization may be due to other immune media-
tors, including cell-mediated immunity.
Our study indicated that the threshold of CPS antibody
associated with signiﬁcantly reduced odds of acquisition of GBS
was 3 μg/mL for serotypes Ia and III and 1 μg/mL for
serotype V. Furthermore, serotype-speciﬁc OPA titres of 8
were associated with similarly reduced odds of new acquisition
of the homotypic serotype for serotypes Ia and III. The OPA
titres correlated more strongly than IgG concentrations in
relation to new acquisition of serotypes Ia and III. This shows
the importance of measuring functional antibody in the evalu-
ation of immune responses to GBS conjugate vaccine. Also, the
correlation between OPA titres and CPS IgG concentration
was modest, suggesting either impaired functional activity of
antibody or limitations of the serology assay with respect to
purity of antigens used or possible role of IgM antibodies in
opsonophagocytosis [33].
Previous studies on the association of GBS colonization and
serum IgG antibody have mainly been cross-sectional studies
and have generally reported higher serotype-speciﬁc CPS
antibody in colonized compared to noncolonized pregnant
women for the homotypic serotype [15–22]. These studies
were, however, not designed to address whether CPS antibody
reduces the risk of GBS colonization during pregnancy, as
shown by us. Nevertheless, the ﬁndings of the previous studies
are conﬁrmed in our study, where higher serotype-speciﬁc CPS
IgG concentrations were also observed in women colonized by
the homotypic serotype compared to those not colonized
when analysed cross-sectionally at either visit 1 or visit 4 for
serotypes Ia and III. This higher antibody concentration in
colonized women in such studies likely reﬂect recent acquisi-
tion of that serotype, which induced the higher antibody levels
compared to women not colonized, as demonstrated by the
kinetics of the antibody response to new acquisitions in our
study.
Our study has certain limitations. Firstly, although we
explored for thresholds of serotype-speciﬁc CPS IgG and OPA
titres associated with reduced odds of new acquisition by
homotypic serotypes, the ﬁndings need to be interpreted with
caution in the absence of a standardized reference assay to
measure either CPS antibody or OPA titres [34]. We tried to
optimize the comparability of our assay to that of other labo-
ratories by calibrating our in-house reference (Polygam) with
reference sera from C. J. Baker, who has published widely in the
ﬁeld. Secondly, the sensitivity of detection of GBS on selective
media is estimated at 85% and mainly identiﬁes the dominantious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e13–568.e21
TABLE 4. Comparison of mean titres (μg/mL) at visits 1 and 4 for pregnant women for speciﬁc serotypes who acquired GBS and
those who remained uncolonized
Serotype
Serotype-speciﬁc new acquisition Uncolonized by speciﬁc serotype
Visit 1 Visit 4
pa
Visit 1 Visit 4
paSerum IgG GMC (95% CI) GMC (95% CI) GMC (95% CI) GMC (95% CI)
Ia 0.32 (0.18, 0.57); n = 42 0.86 (0.44, 1.70) 0.001 0.36 (0.28, 0.46); n = 387 0.40 (0.32, 0.51) 0.169
III 0.14 (0.09, 0.22); n = 35 0.26 (0.15, 0.46) 0.004 0.32 (0.28, 0.38); n = 414 0.30 (0.26, 0.36) 0.272
V 0.38 (0.23, 0.61); n = 15 0.76 (0.43, 1.33) 0.034 0.75 (0.66, 0.84); n = 471 0.83 (0.74, 0.93) 0.011
OPA GMOPT (95% CI) GMOPT (95% CI)
Ia 5 (4, 6); n = 42 110 (53, 227) <0.0001 Not doneb
III 17 (9, 32); n = 35 776 (528, 1143) <0.0001
Comparisons of serum GMC serotype-speciﬁc capsular IgG antibody (μg/mL) and GMOPT at enrolment and end of study in pregnant women who acquired GBS and those who
remained uncolonized throughout.
CI, conﬁdence interval; GBS, group B Streptococcus; GMC, geometric mean concentration; GMOPT, geometric mean opsonophagocytic activity titre; OPA, opsonophagocytic
activity.
ap value by paired Student’s t test.
bOPA at visit 4 was done only for participants who acquired GBS serotype.
CMI Kwatra et al. Immunity against Streptococcus rectovaginal colonization 568.e20colonizing serotype, with lower-density co-colonizing serotypes
likely being missed [23]. Therefore, it is possible that we
overestimated new acquisition through missing colonization
episodes not detectable by standard culture methods at visit 1,
and we similarly may also have missed some new acquisitions.
In summary, our results indicate that the effect of GBS
conjugate vaccine on rectovaginal GBS colonization warrants
further investigation. This could provide rectovaginal coloni-
zation as a surrogate end point to evaluate the potential effect
of GBS conjugate vaccine in protecting newborns (including
those born prematurely) from exposure to GBS at birth and
hence reduce their risk of EOD. A monovalent GBS serotype III
conjugate vaccine has already been reported to signiﬁcantly
reduce the rate of rectovaginal GBS acquisition among
nonpregnant women (Hillier SL, et al. Program and Abstracts of
the 47th Infectious Diseases Society of America annual meeting,
abstract 186). This potential effect of vaccination with GBS
vaccine targeted at women against rectovaginal colonization
may be over and above the additional protection of vaccination
against invasive GBS disease in young infants born at full term,
which is likely to be conferred through transplacental acquisi-
tion of protective serotype-speciﬁc CPS antibody. Further-
more, it is plausible that reducing the risk of GBS acquisition
during pregnancy could reduce the incidence of GBS-associated
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